The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
-
Int. J. Tuberc. Lung Dis. · Jan 2002
Randomized Controlled Trial Clinical TrialRifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures.
Clinical trial in 672 patients with newly diagnosed pulmonary tuberculosis in Hong Kong. After an initial 2 months of a four-drug intensive phase consisting of thrice-weekly streptomycin, isoniazid, rifampicin and pyrazinamide (SHRZ), a random allocation was made to a continuation phase of once-weekly 600 mg rifapentine + 15 mg/kg isoniazid (HRp1), HRp1 given in 2 of every 3 weeks (HRp1.2/3), or to thrice-weekly isoniazid + rifampicin (HR3), the standard treatment in Hong Kong. ⋯ The two rifapentine regimens were unsatisfactory because of their high incidence of adverse events. Isoniazid appeared not to contribute to preventing relapse. Further studies with increased rifapentine dosage are necessary.
-
Int. J. Tuberc. Lung Dis. · Jan 2002
Underdiagnosis of chronic obstructive pulmonary disease in Northern Sweden.
To assess underdiagnosis of chronic obstructive pulmonary disease. ⋯ Approximately 60% of the subjects with chronic airflow limitation had been diagnosed prior to the survey as having asthma, chronic bronchitis or emphysema, or were using asthma medicines. The results were similar in 1986-1987 and 1993-1994.